Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Wall Street is looking to stabilize following last night's 473 point fall for the DJIA, as Chinese t...
Allergan Plc (AGN) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Manisha Narasimhan - Vice President of Investor Relations and Strategic Initiatives Brent Saunders - President and Chief Executive Officer Bill Meury - Executive Vice President and C...
The following slide deck was published by Allergan plc in conjunction with their 2019 Q1 earnings Read more ...
Allergan ( AGN ) Q1 results : Revenues: $3,597.1M (-2.0%); US Specialized Therapeutics: $1,542.9M (-2.8%); US General Medicine: $1,249.9M (+2.1%); International: $801.5M (-7.2%). More news on: Allergan plc, Healthcare stocks news, Earnings news and commentary, Read more ...
May 7, 2019 Palm Beach, FL –May 7, 2019 – The patient demand for a better way to treat to glaucoma has been growing for years. Two recent reports from Transparency Market Research show that this growing worldwide consumer demand projects ever increasing revenues for both th...
Establishment Labs Could Become The Next Hot Medtech Growth Stock Establishment Labs ( ESTA ) manufactures and sells medical devices for aesthetic and reconstructive plastic surgery. It primarily offers silicone gel-filled smooth category breast implants under the Motiva Implants brand nam...
Allergan (NYSE: AGN ): Q1 Non-GAAP EPS of $3.79 beats by $0.22 ; GAAP EPS of -$7.25. More news on: Allergan plc, Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , May 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its first quarter 2019 financial results including GAAP net revenues of $3.60 billion , a 2.0 percent decrease from the prior year quarter. FIRST QUARTER 2019 FINANCIAL RESULTS Executive Com...
Allergan (NYSE: AGN ) is scheduled to announce Q1 earnings results on Tuesday, May 7th, before market open. The consensus EPS Estimate is $3.57 (-4.5% Y/Y) and the consensus Revenue Estimate is $3.55B (-3.3% Y/Y). Over the last 2 years, agn has beaten EPS estimates 100% of the time a...
SAN FRANCISCO and DUBLIN , May 6, 2019 /PRNewswire/ -- Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented new six-year data from Medicin...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...
2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...
2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...